

Research Article

Apolipoprotein M Serum Levels Correlate with IgA Vasculitis and IgA Vasculitis Nephritis

Jiali Wu, Lagu He, Le Bai, Li Tan, and Min Hu 

Department of Laboratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China

Correspondence should be addressed to Min Hu; huminjk@csu.edu.cn

Received 10 July 2019; Accepted 28 November 2019; Published 11 December 2019

Academic Editor: Robert Pichler

Copyright © 2019 Jiali Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. IgA vasculitis (IgAV) is the most frequent vessel vasculitis in children, and the prognosis is related to the children's age and degree of nephritis. This study is aimed at investigating serum apolipoprotein M (apoM) levels in patients with IgAV patients and at evaluating the association between apoM and disease severity. **Methods.** A total of 109 IgAV patients and 76 age- and sex-matched healthy controls were included. The age and gender of the study participants were matched. ApoM levels were measured by an enzyme-linked immunosorbent assay. Additionally, the serum levels of lipids, apolipoproteins, kidney biochemical profiles, immunoglobulins (IgA, IgG, IgM, and IgE), and the complements (C3 and C4) were assessed using an automatic biochemical analyzer. **Results.** ApoM was increased significantly in IgAV patients compared to healthy controls. ApoM, meanwhile, was lower in patients with nephritis than in those without nephritis. The apoM levels were higher in classes I and II IgA vasculitis nephritis (IgAVN) patients than in classes III and IV. Besides, the apoM serum level < 24.81 mg/L was an independent predictive factor for IgAVN and can be independently associated with the presence of nephritis in IgAV patients. Meanwhile, the serum apoM concentration negatively correlated with the ISKDC grading score in IgAVN patients. **Conclusions.** Serum apoM was elevated in IgAV patients and decreased gradually with the ISKDC grading score. ApoM (OR = 0.32, 95%CI = 0.12-0.85, $p = 0.023$) was identified as a protective factor for nephritis in all IgAV patients.

1. Introduction

IgAV is the most common vessel vasculitides in children, which is self-limited. The incidence of IgAV has been increasing in recent years, which varies from 10 to 30 cases per 100,000 children younger than 17 years [1, 2]. It is characterized clinically by palpable purpura, arthrocele or arthralgia, gastrointestinal symptoms, and renal disease [3].

The prognosis is related to the children's age and degree of nephritis. The nephritis is called IgA vasculitis nephritis (IgAVN), which develops in 30%–50% of patients with IgAV [4]. IgAVN is potentially the most severe complication, and the prognosis is mostly dependent on the severity of nephritis [5, 6]. It was pointed out that 12.8% of IgAVN patients had an unfavourable outcome [4, 7].

Apolipoprotein M (apoM) is a 26 kD apolipoprotein that is a member of the lipocalin protein superfamily and is exclusively expressed in hepatocytes and kidney tubular

cells [8, 9]. ApoM exerts a variety of biological functions, such as antioxidative function [10], anti-inflammatory function [11], promoting pre- β HDL formation [12], and increasing cholesterol efflux from foam cells [13]. Several studies reported that apoM plays important roles in diabetes mellitus (DM) [14, 15], endothelial inflammation [16], and coronary artery disease (CAD) [17].

However, the study of evaluating apoM in IgAV, an inflammatory disease of the small blood vessels, and its complication, IgAVN, has never been reported before. Therefore, the purpose of this study was to investigate whether apoM is changed in IgAVN patients and to evaluate its possible association with disease severity.

2. Methods

2.1. Subjects. The patients were recruited from the Second Xiangya Hospital between March 2017 and December 2017.

One hundred eighty-five children were enrolled in this study, with 109 IgAV patients and 76 healthy children. The European League against Rheumatism and Pediatric Rheumatology European Society (EULAR/PReS) criteria was used to diagnose IgAV: palpable purpura must be present (mandatory criterion) in association with at least one of the following: arthritis or arthralgia, diffuse abdominal pain, any biopsy showing a predominant IgA deposition, and/or nephritis (hematuria and/or proteinuria). The IgAVN group comprised patients with IgAV showing nephritis (hematuria and/or proteinuria) [18]. The exclusion criteria for IgAV were as follows: (1) receiving any steroid or immunosuppressant treatments before blood samples were collected; (2) accompanied with diabetes, thrombocytopenic purpura, and liver or other kidney diseases. The histological grades of the renal biopsy were graded in accordance with the International Study of Kidney Disease in Children (ISKDC) classification [19] as follows: class I, minor glomerular abnormalities; class II, pure mesangial proliferation; class III, minor glomerular abnormalities or mesangial proliferation, with crescents/segmental lesions (sclerosis, adhesion, thrombosis, and necrosis) in <50% of the glomeruli; class IV, same as class III but with crescents/segmental lesions in 50–75% of the glomeruli; and class V, same as class III but with crescents/segmental lesions in >75% of the glomeruli; the vascular component was graded as follows: class 1, essentially normal; class 2, <25%; class 3, 25% to 50%; and class 4, >50% [20].

2.2. Blood Sampling. After an overnight fast and 30 min rest, blood samples were collected from each subject. Serum was obtained by centrifugation at 3500 rpm for 5 min, and aliquots were stored at -80°C for analysis.

2.3. Enzyme-Linked Immunosorbent Assay (ELISA) for apoM Assessment. Serum apoM levels were measured using a sandwich ELISA (Yuan Tai Bio Inc., Changsha, Hunan, China). Optical density (OD) was measured at 450 nm (with the background reading at 620 nm) on an ELX-800 absorbance reader (BioTek Instruments, Inc., Winooski, VT, USA). The concentration of apoM (as mg/L) in each sample was derived from a standard curve.

2.4. Laboratory Examination. Levels of serum blood urea nitrogen (BUN), creatinine (CRE), uric acid (UA), triglyceride (TG), total cholesterol (TC), HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), apolipoprotein A (apoA), apolipoprotein B (apoB), and C-reactive protein (CRP) levels were determined using an ARCHITECTc8000 System (Abbott Laboratories, Irving, TX, USA). Levels of serum immunoglobulins (IgA, IgG, IgM, and IgE) and the complements (C3 and C4) were determined using Beckman IMMAGE800.

2.5. Statistical Analysis. Continuous data are presented as median (range), and categorical data are expressed as percentages. Continuous data were analyzed with the Student *t*-test or one-way analysis of variance (one-way ANOVA) for traits with the normal distribution. Pearson's correlation analysis was used to test for associations between apoM and variables with a normal distribution. The Spearman correla-

tion analysis was used to analyze variables with skewed distributions. Binary logistic regression models were carried out to identify the risk factors for IgAVN patients. All analyses were performed with SPSS 20.0 (SPSS, USA) or GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, USA). Two-sided $p < 0.05$ was considered statistically significant.

3. Results

3.1. Clinical Characteristics of the Study Subjects. One hundred nine IgAV patients were included in the study, with 63 boys and 43 girls ranging in age from 1 to 15 (9.04 ± 0.71) years. Among the 109 IgAV patients, 43 patients developed nephritis (IgAVN). Among the 43 IgAVN patients, there are 25 patients with only purpura, 8 patients with purpura and arthritis, 8 patients with purpura and abdominal pain, and 2 patients with purpura, arthritis, and abdominal pain. Among the 66 IgAV patients, there are 31 patients with only purpura, 18 patients with purpura and arthritis, 12 patients with purpura and abdominal pain, and 5 patients with purpura, arthritis, and abdominal pain.

No statistical differences in age (7.88 ± 3.024 , 9.42 ± 4.32 , and 8.79 ± 4.04) and gender were observed among healthy controls, IgAVN, and IgAV without nephritis groups (all $p > 0.05$).

3.2. The Serum Lipid Levels and Apolipoprotein Levels in Healthy Controls, IgAVN, and IgAV without Nephritis Patients. The serum lipid levels in the three groups are shown in Table 1; compared with the healthy controls, IgAVN and IgAV without nephritis patients had significantly higher serum TC and LDL-C levels.

Meanwhile, there was no significant difference between the healthy controls, IgAVN patients, and IgAV without nephritis patients in average HDL-C serum levels or apoB serum levels (Figure 1(a)).

3.3. The Serum Kidney Biochemical Profile Levels in Healthy Controls, IgAVN Patients, and IgAV without Nephritis Patients. As shown in Table 1, the serum CRE levels of IgAV patients were significantly higher than those of the healthy subjects. Notably, the serum CRE and UA levels of the patients in the IgAVN group were even higher than those observed in the IgAV without nephritis group.

Meanwhile, there was no significant difference between the healthy controls, IgAVN patients, and IgAV without nephritis patients in average BUN serum levels (Figure 1(b)).

3.4. Comparison of Immune Function in IgAV without Nephritis Patients and IgAVN Patients. The serum IgG and C4 levels of the patients in the IgAV without nephritis group were even higher than those observed in the IgAVN group.

Meanwhile, there was no significant difference between IgAVN patients and IgAV without nephritis patients in average C3, IgM, IgA, or IgE levels (Figures 1(c) and 1(d)).

3.5. Serum apoM Levels Are Elevated in IgAV Patients. Kidney biopsy was performed on IgAVN patients. According to the ISKDC classification, 18 patients were in classes I and II,

TABLE 1: Clinical and biochemical characteristics of the study subjects.

	Healthy control	IgAVN	IgAV without nephritis	<i>p</i>
Subjects, <i>n</i>	76	43	66	
Demographics				
Age	7.88 ± 3.024	9.42 ± 4.32	8.79 ± 4.04	>0.05
Gender (male/female)	44/32	26/17	37/29	>0.05
Lipid profiles				
TG (mmol/L)	2.75 (1.12-3.39) ^b	1.26 (0.8-1.66) ^a	1.08 (0.67-1.87) ^a	<0.05
TC (mmol/L)	0.84 (0.59-2.99) ^b	3.93 (3.44-4.56) ^a	3.98 (3.19-4.85) ^a	<0.05
HDL-C (mmol/L)	1.23 (1.05-1.37)	1.21 (1-1.36)	1.29 (1.03-1.55)	>0.05
LDL-C (mmol/L)	1.9 (1.5-2.16) ^b	2.21 (1.77-2.75) ^a	2.1 (1.57-2.78) ^a	<0.05
apoA (g/L)	1.06 (0.99-1.15) ^b	0.9 (0.75-1.04) ^a	0.93 (0.78-1.06) ^a	<0.05
apoB (g/L)	0.57 (0.47-0.66)	0.58 (0.49-0.7)	0.58 (0.45-0.72)	>0.05
apoM (mg/L)	18.17 (15.83-20.22) ^a	23.92 (21.25-26.1) ^b	25.96 (23.50-27.46) ^c	<0.05
Kidney biochemical profiles				
BUN (μmol/L)	3.8 (3.25-4.47)	4.02 (2.86-5.5)	4.09 (2.99-4.95)	>0.05
CRE (μmol/L)	30.9 (24.23-36.4) ^a	41.1 (36-53) ^b	35.55 (30.75-42.43) ^c	<0.05
UA (g/L)	230.05 (181.93-269.63) ^a	265 (218.6-330.3) ^b	223.3 (187.13-281.55) ^a	<0.05
hs-CRP (mg/L)	/	1.94 (1.02-3.87)	3.74 (1.37-12.1)	<0.05
Immunoglobulins				
IgG (g/L)	/	8.4 (6.16-11)	9.97 (8.29-11.7)	<0.05
IgM (g/L)	/	2 (1.54-2.35)	2.2 (1.52-3.19)	>0.05
IgA (g/L)	/	1.25 (0.84-1.42)	1.05 (0.87-1.56)	>0.05
IgE (g/L)	/	150.8 (59.09-447.3)	275.05 (119.38-298.63)	>0.05
Complements				
C3 (g/L)	/	0.95 (0.8-1.13)	1 (0.9-1.15)	>0.05
C4 (g/L)	/	0.18 (0.15-0.23)	0.23 (0.18-0.28)	<0.05

abc means not sharing a common superscript are significantly different among the healthy controls, IgAVN, and IgAV without nephritis groups at $p < 0.05$. Data are presented as median (range). TG: triglyceride; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; apoA1: apolipoprotein A1; apoB: apolipoprotein B; apoM: apolipoprotein M.

and 25 patients were in classes III and IV (13 in class IIIa, 7 in class IIIb, 5 in class IV).

Serum apoM levels in IgAV patients were higher than values obtained for healthy controls. The most pronounced apoM increase in IgAVN patients was observed in classes III and IV (21.62 (19.16-23.7984) mg/L), followed by classes I and II (25.72 (24.58-27.3) mg/L, $p < 0.05$; Figure 2).

3.6. Association between Serum apoM and ISKDC in IgAVN Patients. As showed in Table 2, the serum apoM concentration negatively correlated with ISKDC in the IgAVN patients ($r = -0.693$, $p < 0.001$). Besides, ISKDC score negatively correlated with IgG in the IgAVN patients ($r = -0.348$, $p = 0.022$) (Table 2).

3.7. Predictive Factors for Nephritis. To identify the risk factors associated with IgAVN, a binary logistic regression model of the IgAV patients was built. In univariate analysis, apoM (OR = 0.339, 95%CI = 0.181-0.877, $p = 0.022$) was identified as a protective risk factor. In contrast, CRE (OR = 3.753, 95%CI = 1.472-9.572, $p = 0.006$) was found to be a risk factor for IgAVN onset (Table 3).

In multivariate analysis, apoM (OR = 0.37, 95%CI = 0.156-0.877, $p = 0.024$) was identified as a protective factor.

4. Discussion

In this study, we measured the serum apoM levels in IgAV patients and healthy controls and screened for the association between serum apoM levels and ISKDC, a gold standard for severity assessment of renal. We found that apoM increased significantly in IgAV patients compared to healthy controls. ApoM, meanwhile, was lower in patients with nephritis than in those without nephritis. Also, the apoM serum level < 24.81 mg/L was an independent predictive factor for IgAVN and can be independently associated with the presence of nephritis in IgAV patients. Meanwhile, the serum apoM concentration negatively correlated with ISKDC in IgAVN patients.

It is reported that the pathogenesis of IgAV is mainly the humoral immunity mediated by IgA, and the systemic inflammatory response and tissue damage caused by the deposition of IgA on the wall of small blood vessels play an essential role in the pathogenesis of IgA vasculitis [21].




FIGURE 1: Serum concentrations of lipid levels, renal function markers and immunoglobulins, and complements in IgAV patients and healthy controls. (a) IgAV patients exhibit decreased serum TG levels and elevated serum levels of TC and LDL-C. (b) IgAV patients exhibit elevated serum CRE levels. (c) IgAV without nephritis patients have elevated IgG levels. (d) IgAV without nephritis patients have elevated C4 levels. * $p < 0.05$.




FIGURE 2: Serum apoM levels of IgAV patients and healthy controls. (a) apoM levels in IgAV patients were higher than those of healthy controls. (b) ApoM levels in IgA vasculitis nephritis patients with classes I and II were higher than those of patients with classes III and IV.

Several studies have been reported that apoM was reported in metabolic diseases, autoimmune diseases, and inflammatory diseases. These studies proved apoM could be used as a novel potential marker to evaluate disease activity in chronic obstructive pulmonary disease (COPD) [22] and systemic lupus erythematosus (SLE) [23], and recognized as

a critical unfavourable prognostic determinant in COPD and SLE. Meanwhile, apoM is closely related to lipid metabolism. In primary nephrotic syndrome (PNS) [24], serum apoM level is negatively correlated with proteinuria.

In this study, IgAV patients exhibited lower serum levels of apoA and higher serum levels of LDL-C than the control

TABLE 2: Correlation between ISKDC and the serum apoM level.

	<i>R</i>	<i>P</i>
apoM	-0.693	<0.001
TG	0.222	0.152
TC	0.295	0.055
HDL-C	-0.005	0.975
LDL-C	0.209	0.055
apoA	-0.157	0.316
apoB	0.136	0.386
BUN	0.053	0.734
CRE	0.336	0.028
UA	0.133	0.395
IgG	-0.348	0.022
IgM	-0.161	0.302
IgA	0.091	0.562
IgE	0.077	0.624
C3	-0.015	0.926
C4	-0.01	0.951

TABLE 3: Predictive factors of nephritis in IgAV patients.

	OR	95% CI	<i>p</i>	OR	95% CI	<i>p</i>
TG	0.915	0.207-4.043	0.907	1.167	0.228-5.978	0.853
TC	1.44	0.652-3.183	0.368	2.892	0.694-12.058	0.145
HDL-C	0.738	0.339-1.609	0.445	0.622	0.23-1.684	0.35
LDL-C	1.295	0.599-2.803	0.511	0.594	0.169-2.087	0.416
apoA	0.745	0.344-1.612	0.455	0.925	0.379-2.255	0.864
apoB	0.834	0.382-1.822	0.649	0.685	0.261-1.797	0.442
apoM	0.339	0.181-0.877	0.022	0.37	0.156-0.877	0.024
BUN	1.385	0.633-3.033	0.415	1.002	0.411-2.542	0.962
CRE	3.753	1.472-9.572	0.006	2.774	0.934-8.06	0.066
UA	2.195	0.991-4.865	0.053	1.965	0.762-5.066	0.162

subjects. In contrast, these patients also presented with higher serum levels of apoM than the controls.

It is reported that serum apoM has a positive correlation with serum HDL-C [10, 25]. This is particularly true for HDL-C, as approximately 96% of apoM is bound to HDL particles [26]. This may be since most of the apoM is anchored to the HDL. ApoM was shown to be exchanged from HDL-C to LDL-C because of altered HDL-C amounts under inflammatory conditions [27, 28]. These partly can explain why both LDL-C and apoM were increased in IgAV patients, although there was no correlation between them.

In this study, the apoM level was negatively correlated with ISKDC grading scoring, which is a gold standard for the severity assessment of renal. Meanwhile, in multivariate analysis, apoM was the independent predictor of the presence of nephritis in IgAV patients. Serum apoM levels in IgAVN patients were lower than IgAV without nephritis patients. The apoM serum level in the IgAVN patients of

classes I and II was higher than the IgAVN patients of classes III and IV. Some reasons may account for this discrepancy. ApoM is exclusively expressed in kidney tubular cells. The systemic inflammatory response caused by the deposition of IgA causes elevated levels of apoM. The deposition of immune complex in IgAV patients causes the inflammatory reaction, and the expression of inflammatory factors that upregulate apoM increases, leading to an increase of apoM synthesis. Meanwhile, apoM loss was increased due to damage of renal tubular epithelial cells, and the content of apoM decreased with the aggravation of renal damage.

Due to the vital role of apoM in autoimmune disease, it is essential to understand the role of apoM concerning autoimmune diseases. Du et al. [23] reported that serum APOM levels were decreased in patients with SLE and correlated with disease activity. Hu et al. demonstrated that APOM promoter polymorphisms (rs805297 and rs805296) were significantly associated with RA [29]. Meanwhile, APOM C-1065A polymorphism is associated with an increased risk for developing rheumatoid arthritis and dyslipidemia in rheumatoid arthritis patients [30]. Furthermore, Wang et al. [31] showed that apoM could modify T lymphocyte subsets in the murine spleen. Indeed, the ApoM-S1P-S1P1 signalling axis restrains the lymphocyte compartment and, subsequently, adaptive immune responses [32]. Recent studies showed that ApoM-bound S1P reduces endothelial inflammation through sphingosine 1-phosphate receptor 1 (S1P1) [33, 34].

We proposed that apoM-S1P may play a role in resisting inflammation and immune dysfunction in IgAV patients. What is more, it may be used as a potential helpful agent in IgAV patients.

There are several limitations to our present study. First, the number of patients with IgAVN patients was relatively small. Further studies with a larger patient cohort are therefore needed to confirm our findings. Meanwhile, the results of 24h urine volume and urine protein were challenging to obtain in children, and the results of cellular immunity and prognostic analysis were not obtained. These data would help determine whether apoM could be a serum marker to facilitate the management of IgAV in clinical practice or a potential helpful agent in IgAV treatments.

In general, our study found that the apoM level increased in IgAV patients. ApoM loss increased in IgAVN patients due to renal injury, resulting in a decrease in apoM serum level, and the apoM level decreased with the aggravation of the renal injury. The serum apoM level was negatively correlated with the ISKDC grading score in IgAVN patients.

5. Conclusion

The serum apoM level in patients with IgAV was found to be higher than that in healthy controls and negatively correlated with ISKDC grading score in IgAVN patients, reflecting apoM could be a marker of monitoring the progress of IgAVN.

Abbreviations

apoA: Apolipoprotein A
 apoB: Apolipoprotein B
 apoM: Apolipoprotein M
 HDL-C: High-density lipoprotein cholesterol
 LDL-C: Low-density lipoprotein cholesterol
 TG: Triglycerides
 TC: Total cholesterol.

Data Availability

All data generated or analyzed during this study are included in this published article.

Ethical Approval

This study was approved by the Second Xiangya Hospital Investigational Review Board.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors' Contributions

JLW carried out the study design, performed the data collection and analysis, and wrote the manuscript; LGH carried out the enzyme-linked immunosorbent assays; LB analyzed the patients' information; LGH participated in the statistical analysis of the data; LT measured the lipid concentrations; MH provided the funding support, conceived the study, participated in its design and coordination, and provided the critical revision. All authors have read and approved the final manuscript.

Acknowledgments

The authors of this study would like to acknowledge the contribution of the study participants.

References

- [1] K. Penny, M. Fleming, D. Kazmierczak, and A. Thomas, "An epidemiological study of Henoch-Schönlein purpura," *Paediatric Nursing*, vol. 22, no. 10, pp. 30–35, 2010.
- [2] J. M. Gardner-Medwin, P. Dolezalova, C. Cummins, and T. R. Southwood, "Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins," *The Lancet*, vol. 360, no. 9341, pp. 1197–1202, 2002.
- [3] Y. H. Yang, Y. H. Chuang, L. C. Wang, H. Y. Huang, M. E. Gershwin, and B. L. Chiang, "The immunobiology of Henoch-Schönlein purpura," *Autoimmunity Reviews*, vol. 7, no. 3, pp. 179–184, 2008.
- [4] O. Jauhola, J. Ronkainen, O. Koskimies et al., "Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children," *Archives of Disease in Childhood*, vol. 95, no. 11, pp. 877–882, 2010.
- [5] J. C. Davin and R. Coppo, "Henoch-Schönlein purpura nephritis in children," *Nature Reviews Nephrology*, vol. 10, no. 10, pp. 563–573, 2014.
- [6] H. Narchi, "Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review," *Archives of Disease in Childhood*, vol. 90, no. 9, pp. 916–920, 2005.
- [7] O. Soylemezoglu, O. Ozkaya, S. Ozen et al., "Henoch-Schönlein nephritis: a nationwide study," *Nephron Clinical Practice*, vol. 112, no. 3, pp. c199–c204, 2009.
- [8] X. Y. Zhang, X. Dong, L. Zheng et al., "Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization," *Acta Histochemica*, vol. 105, no. 1, pp. 67–72, 2003.
- [9] N. Xu and B. Dahlbäck, "A novel human apolipoprotein (apoM)," *Journal of Biological Chemistry*, vol. 274, no. 44, pp. 31286–31290, 1999.
- [10] S. Elsåe, J. Ahnström, C. Christoffersen et al., "Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL," *Atherosclerosis*, vol. 221, no. 1, pp. 91–97, 2012.
- [11] X. S. Huang, S. P. Zhao, M. Hu, and Y. P. Luo, "Apolipoprotein M likely extends its anti-atherogenesis via anti-inflammation," *Medical Hypotheses*, vol. 69, no. 1, pp. 136–140, 2007.
- [12] C. Wolfrum, M. N. Poy, and M. Stoffel, "Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis," *Nature Medicine*, vol. 11, no. 4, pp. 418–422, 2005.
- [13] C. Christoffersen, M. Jauhiainen, M. Moser et al., "Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice," *Journal of Biological Chemistry*, vol. 283, no. 4, pp. 1839–1847, 2008.
- [14] C. Frej, A. J. Mendez, M. Ruiz et al., "A shift in ApoM/S1P between HDL-particles in women with type 1 diabetes mellitus is associated with impaired anti-inflammatory effects of the ApoM/S1P complex," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 37, no. 6, pp. 1194–1205, 2017.
- [15] M. Liu, C. Frej, C. D. Langefeld et al., "Plasma apoM and S1P levels are inversely associated with mortality in African Americans with type 2 diabetes mellitus," *Journal of Lipid Research*, vol. 60, no. 8, pp. 1425–1431, 2019.
- [16] M. Ruiz, C. Frej, A. Holmér, L. J. Guo, S. Tran, and B. Dahlbäck, "High-density lipoprotein-associated apolipoprotein M limits endothelial inflammation by delivering sphingosine-1-phosphate to the sphingosine-1-phosphate receptor 1," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 37, no. 1, pp. 118–129, 2017.
- [17] L. Zheng, G. Luo, J. Zhang et al., "Decreased activities of apolipoprotein m promoter are associated with the susceptibility to coronary artery diseases," *International Journal of Medical Sciences*, vol. 11, no. 4, pp. 365–372, 2014.
- [18] S. Ozen, A. Pistorio, S. M. Iusan et al., "EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria," *Annals of the Rheumatic Diseases*, vol. 69, no. 5, pp. 798–806, 2010.
- [19] R. Counahan, M. H. Winterborn, R. H. White et al., "Prognosis of Henoch-Schönlein nephritis in children," *British Medical Journal*, vol. 2, no. 6078, pp. 11–14, 1977.

- [20] A. Bohle, G. A. Müller, M. Wehrmann, S. Mackensen-Haen, and J. C. Xiao, "Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides," *Kidney International Supplements*, vol. 49, no. 54, pp. S2–S9, 1996.
- [21] M. H. Heineke, A. V. Ballering, A. Jamin, S. Ben Mkaddem, R. C. Monteiro, and M. van Egmond, "New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura)," *Autoimmunity Reviews*, vol. 16, no. 12, pp. 1246–1253, 2017.
- [22] H. Li, Y. Liu, L. Wang et al., "High apolipoprotein M serum levels correlate with chronic obstructive pulmonary disease," *Lipids in Health and Disease*, vol. 15, no. 1, pp. 1–7, 2016.
- [23] W. Du, T. Shen, H. Li et al., "Low apolipoprotein M serum levels correlate with systemic lupus erythematosus disease activity and apolipoprotein M gene polymorphisms with lupus," *Lipids in Health and Disease*, vol. 16, 2017.
- [24] L. He, P. Wu, L. Tan et al., "Characteristics of lipid metabolism including serum apolipoprotein M levels in patients with primary nephrotic syndrome," *Lipids in Health and Disease*, vol. 16, no. 1, pp. 167–175, 2017.
- [25] G. Luo, X. Zhang, P. Nilsson-Ehle, and N. Xu, "Apolipoprotein M," *Lipids in Health and Disease*, vol. 3, no. 1, p. 21, 2004.
- [26] C. Christoffersen, L. B. Nielsen, O. Axler, A. Andersson, A. H. Johnsen, and B. Dahlbäck, "Isolation and characterization of human apolipoprotein M-containing lipoproteins," *Journal of Lipid Research*, vol. 47, no. 8, pp. 1833–1843, 2006.
- [27] W. Khovidhunkit, R. A. Memon, K. R. Feingold, and C. Grunfeld, "Infection and inflammation-induced proatherogenic changes of lipoproteins," *The Journal of Infectious Diseases*, vol. 181, article S462, Supplement 3S472 pages, 2000.
- [28] P. M. Clifton, A. M. Mackinnon, and P. J. Barter, "Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction," *Journal of Lipid Research*, vol. 26, no. 12, pp. 1389–1398, 1985.
- [29] H. J. Hu, E. H. Jin, S. H. Yim et al., "Common variants at the promoter region of the APOM confer a risk of rheumatoid arthritis," *Experimental and Molecular Medicine*, vol. 43, no. 11, pp. 613–621, 2011.
- [30] Y. J. Park, S. A. Yoo, J. H. Lee, Y. J. Chung, C. S. Cho, and Kim W., "The APOM polymorphism as a novel risk factor for dyslipidaemia in rheumatoid arthritis: a possible shared link between disease susceptibility and dyslipidaemia," *Clinical and Experimental Rheumatology*, vol. 31, no. 2, pp. 180–188, 2012.
- [31] Z. Wang, G. Luo, Y. Feng et al., "Decreased Splenic T-Lymphocytes in Apolipoprotein M Gene Deficient Mice," *BioMed Research International*, vol. 2015, Article ID 293512, 8 pages, 2015.
- [32] V. A. Blaho, S. Galvani, E. Engelbrecht et al., "HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation," *Nature*, vol. 523, no. 7560, pp. 342–346, 2015.
- [33] P. M. Christensen, C. H. Liu, S. L. Swendeman et al., "Impaired endothelial barrier function in apolipoprotein M-deficient mice is dependent on sphingosine-1-phosphate receptor 1," *The FASEB Journal*, vol. 30, no. 6, pp. 2351–2359, 2016.
- [34] S. Galvani, M. Sanson, V. A. Blaho et al., "HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation," *Science Signaling*, vol. 8, no. 389, article ra79, 2015.



Hindawi

Submit your manuscripts at
www.hindawi.com

